Sight Sciences, Inc., a Menlo Park, CA-based commercial stage ophthalmic medical device company, closed a $10m Series C round of growth financing.
The round was led by Allegro Investment Fund, with participation from all existing Series A and Series B investors.
The company intends to use the funds to build out its commercial team in the United States, launch its ophthalmic devices in Dry Eye and Microinvasive Surgery, scale up manufacturing, and complete clinical studies geared towards expanded product indications and strategic product positioning.
Led by Paul Badawi, President and CEO, and newly appointed Senior Vice President of Sales and Marketing, Shawn O’Neil, Sight Sciences is a medical device company dedicated to the development of technology-driven solutions that address the underlying physiology of ophthalmic diseases. The company operates two business lines: surgical and non-surgical devices.
Its surgical product portfolio consists of the TRAB®360 and VISCO360® surgical devices and another surgical device in an advanced stage of development. Its non-surgical product portfolio consists of technologies for dry eye disease.
The VISCO360® Viscosurgical System and TRAB®360 Trabeculotomy System are commercially available in the United States, Europe and Canada. The VISCO360® device is available in the United States as a manual surgical tool and is investigational in the United States for the specific indication of IOP reduction in adult, pseudophakic patients with primary open angle glaucoma.